Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-label Trial in Healthy Subjects to Evaluate the Drug-drug Interaction Between Ritonavir at Steady-state and TMC435350, a Viral Protease Inhibitor Against Hepatitis C Virus, After the First and the Last Dose of a Multiple Dosing Regimen

NCT01891851 is registered in ClinicalTrials.gov with Tibotec Pharmaceuticals, Ireland as lead sponsor.

NCT NCT01891851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01891851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-label Trial in Healthy Subjects to Evaluate the Drug-drug Interaction Between Ritonavir at Steady-state and TMC435350, a Viral Protease Inhibitor Against Hepatitis C Virus, After the First and the Last Dose of a Multiple Dosing Regimen
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2007
Completion date
January 31, 2008
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy